Dissertation Dr. med. Ekkehard Reischle - Privatklinik Dr. Reischle

8.0 Literatur
1
Seeman, P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 47, 27-38 (2002)
2
Haase, H.J. [Occurrence and interpretation of psychomotor parkinsonism in megaphen or largactil
prolongedtherapy.]. Nervenarzt 25, 486-92 (1954).
3
Farde, L. et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor
occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side
effects. Arch Gen Psychiatry 49, 538-44 (1992).
4
Laborit, H.,Huguennard,R.,Alluaume,R..Un nouveau stabilisateur neuro-vegetatif le 4560 RP.Press.Med
60,260(1952)
5
Delay, J., Deniker, P., Harl & Grasset, A. [N-dimethylamino-prophylchlorophenothiazine (4560 RP)
therapy of confusional states.]. Ann Med Psychol (Paris) 110, 398-403 (1952).
6
Davis, J.M, Casper, R. C. General principles of the clinical use of neuroleptics. In: Clark, W.G.,DeL
Guidice;J(eds) principles of Psychopharmacology, New York San Francisco London: 2 nd ed.Academic
Press;pp 511- 536 (1998)
7
Baldessarini, R.J. Clinical and epidemiologic aspects of tardive dyskinesia. J Clin Psychiatry 46, 8-13
(1985).
8
Eichelbaum, M. & Gross, A.S. The genetic polymorphism of debrisoquine/sparteine metabolism—clinical
aspects. Pharmacol Ther 46, 377-94 (1990).
9
Rijcken, C.A., Monster, T.B., Brouwers, J.R. & de Jong-van den Berg, L.T. Chlorpromazine equivalents
ver sus defined daily doses: how to compare antipsychotic drug doses? J Clin Psychopharmacol 23, 657-
9(2003).
10
Enss, H.,Hartmann, K., Hippius, H.,Richter,H.E.: klinische Erfahrungen mit einem neuen Piperazin –
Derivat des Phenothiazins in der Neuro-Psychiatrie. Sonderdruck aus: Archiv für Neurologie und Nervenkrankheiten
197,5,534-550 (1958).
11 Seeman, P. Brain dopamine receptors. Pharmacol Rev 32, 229-313 (1980).
12 Breyer-Pfaff, U., Brinkschulte, M., Rein, W., Schied, H.W. & Straube, E. Prediction and evaluation
criteria in perazine therapy of acute schizophrenics. Pharmacokinetic data. Pharmacopsychiatria 16, 160-
5 (1983).
13 Bauer, D. & Gaertner, H.J. [Effects of neuroleptics on liver function, the hematopoietic system, blood
pressure and temperature regulation. Comparison of clozapine, perazine and haloperidol by evaluating
medical records]. Pharmacopsychiatria 16, 23-9 (1983).
14 Pietzcker, A., Poppenberg, A., Schley, J. & Muller-Oerlinghausen, B. Outcome and risks of ultra-longterm
treatment with an oral neuroleptic drug. Relationship between perazine serum levels and clinical
variables in schizophrenic outpatients. Arch Psychiatr Nervenkr 229, 315-29 (1981).
15 Malin,J.P., Rosenberg,L., Multidimensionale pharmakopsychiatrische Untersuchungen mit dem Neurolep
tikum Perazin. 5. Mitteilung: Beeinflussung der ventrikulären Erregungsrückbildung im Elektrokardiogramm.Pharmakopsychiatrie
7: 41-49 (1974)
16 Grohmann, R., Koch, R. & Schmidt, L.G. Extrapyramidal symptoms in neuroleptic recipients. Agents
Actions Suppl 29, 71-82 (1990).
17 Lohmann, T., Ferbert, A. & Ebel, H. A unique case of tardive dystonia induced by short-term therapy with
perazin. Pharmacopsychiatry 28, 263-5 (1995).
18 Roelcke, U. et al. “Sunbath polyneuritis”: subacute axonal neuropathy in perazine-treated patients after
intense sun exposure. Muscle Nerve 19, 438-41 (1996).
19 Mollering, M. [Perazine-induced agranulocytosis—case report]. Z Kinder Jugendpsychiatr 16, 27-30
(1988).
20 Krueger, H.J. & Schwarz, H. [New aspects of long-term neuroleptic therapy in psychiatric dispensaries
and clinics.]. Med Welt 9, 463-7 (1963).
21 Hippius,H.,Selbach, H..Zur medikamentösen Dauertherapie bei Psychosen. Neuropsychopharmakologie,
2.Symposium,Nürnberg Med.Exp.5, 298-305 (1961).
80